*Department of Hepatobiliary Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550001, China.
Jpn J Clin Oncol. 2014 Feb;44(2):159-67. doi: 10.1093/jjco/hyt194. Epub 2013 Dec 26.
The roles of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in the development of hepatocellular carcinoma have not been fully elucidated. Here, we aim to uncover the relationship between the prognosis of hepatocellular carcinoma patients and the expression of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in tumor tissues.
The protein levels of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α were detected by immunohistochemistry on paraffin sections of 126 paired hepatocellular carcinoma tissue and peritumoral tissue samples. The mRNA levels of them were detected by quantitative real-time polymerase chain reaction.
High expression of hypoxia-inducible factor-1α was found in 57.1% (72/126) of tumor specimens, compared with 5.6% (7/126) in peritumoral tissues, while high expression of hypoxia-inducible factor-2α was found in only 13.5% (17/126) of tumors, compared with 47.6% (60/126) of peritumoral tissues. There was high expression of hypoxia-inducible factor-1α protein in hepatocellular carcinoma tissues closely associated with capsular infiltration and portal vein invasion, and thus lower overall survival and disease-free survival of hepatocellular carcinoma patients (P < 0.05). No significant association has been found between the expression of hypoxia-inducible factor-2α protein and capsular infiltration, portal vein invasion, overall survival and disease-free survival (P > 0.05). However, patients with high expression of both hypoxia-inducible factor-1α and hypoxia-inducible factor-2α have a significantly worse outcome than patients with low expression of both hypoxia-inducible factor-1α and hypoxia-inducible factor-2α (P < 0.05).
The discordant results on expression of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α suggest that these two proteins are differentially regulated in vivo, thus reflecting distinctive protein expression and stabilization mechanisms. The association between hypoxia-inducible factor-1α expression and unfavorable outcome indicates the importance of using hypoxia-inducible factor-1α as a treatment target in hepatocellular carcinoma.
缺氧诱导因子-1α(Hypoxia-inducible factor-1α,HIF-1α)和缺氧诱导因子-2α(Hypoxia-inducible factor-2α,HIF-2α)在肝细胞癌(Hepatocellular carcinoma,HCC)发展中的作用尚未完全阐明。本研究旨在探讨肿瘤组织中 HIF-1α 和 HIF-2α 的表达与 HCC 患者预后的关系。
采用免疫组织化学方法检测 126 对 HCC 组织及其癌旁组织石蜡切片中 HIF-1α 和 HIF-2α 的蛋白表达水平,采用实时定量聚合酶链反应(quantitative real-time polymerase chain reaction,qRT-PCR)检测其 mRNA 表达水平。
HIF-1α 在肿瘤组织中的高表达率为 57.1%(72/126),显著高于癌旁组织的 5.6%(7/126);HIF-2α 在肿瘤组织中的高表达率仅为 13.5%(17/126),显著低于癌旁组织的 47.6%(60/126)。HIF-1α 蛋白在 HCC 组织中的高表达与包膜浸润和门静脉侵犯密切相关,导致 HCC 患者的总生存(Overall survival,OS)和无病生存(Disease-free survival,DFS)率降低(P < 0.05)。HIF-2α 蛋白的表达与包膜浸润、门静脉侵犯、OS 和 DFS 均无显著相关性(P > 0.05)。然而,HIF-1α 和 HIF-2α 均高表达的患者的预后明显差于 HIF-1α 和 HIF-2α 均低表达的患者(P < 0.05)。
HIF-1α 和 HIF-2α 的表达结果不一致提示这两种蛋白在体内可能受到不同的调控,从而反映出不同的蛋白表达和稳定机制。HIF-1α 表达与不良预后相关表明,将 HIF-1α 作为 HCC 的治疗靶点具有重要意义。